Back to discover
Drug

Patisiran sodium

Approved · EMA

Also known as Onpattro, patisiran (as sodium).

RxNorm2053491
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Patisiran sodium
Aliases & brands
Onpattropatisiran (as sodium)
RxNorm CUI
2053491
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2018-08-27
Latest approval
2018-08-27
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2018-08-27Accelerated approval
Accelerated approval: Onpattro (EMA)

Indication: Onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Regulatory event sources are credited in the Regulatory Timeline above.